Moreover, the results observed in PAP as well as LTM of NOR indicated that DL77 ameliorated cognitive deficits through blockade of H3Rs, demonstrating the therapeutic prospective of H3R antagonists in the future treatment of neurodegenerative diseases, e.g., AD. Here, HRH3 is linked to neurodegenerative disease.